EPISODE · Nov 4, 2025 · 10 MIN
BIO-Europe 2025: Barcelona based Connecta Therapeutics is moving its neuroplasticity modulator for fragile X syndrome into a phase 2a study after completing first in human studies late last year
from BiotechTV - News · host BiotechTV
CEO Jordi Fàbrega and CFO Josep Prous discusses the asset, CTH120, which is a NCE and proprietary to Connecta.
Embed this episode
NOW PLAYING
BIO-Europe 2025: Barcelona based Connecta Therapeutics is moving its neuroplasticity modulator for fragile X syndrome into a phase 2a study after completing first in human studies late last year
0:00
10:52
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 10 minutes long.
When was this BiotechTV - News episode published?
This episode was published on November 4, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!